Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Di Maio

Showing results (11-20 of 418) with videos related to

Pageof 42
Sort By:
Pharmaceutical Medicine|May 14, 2025
Association Between Health-Related Quality of Life Measures and Survival Endpoints in Oncology Clinical Trials and in Clinical Decision Making: A Narrative ReviewAnna Amela Valsecchi, Massimo Di Maio
Recenti Progressi in Medicina|August 6, 2019
[Description of adverse events in publications of clinical trials: much room for improvement.]Massimo Di Maio, Andrea Antonuzzo, Paolo Bossi
Cancer Treatment Reviews|October 23, 2012
Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practiceAntonio Rossi, Olga Martelli, Massimo Di Maio
Cancers|September 19, 2020
Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized TrialsFrancesco Facchinetti, Massimo Di Maio, Marcello Tiseo
Expert Review of Respiratory Medicine|February 3, 2017
Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancerAntonio Rossi, Anna La Salvia, Massimo Di Maio
Cancer Management and Research|June 18, 2020
Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The EvidenceEmmanuele De Luca, Donatella Marino, Massimo Di Maio
Translational Lung Cancer Research|March 10, 2016
Raising the bar for enthusiasm when looking at results of randomized phase II trials-the case of sunitinib in small-cell lung cancerMassimo Di Maio, Paolo Bironzo, Giorgio Vittorio Scagliotti
Oncology and Therapy|February 21, 2026
Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus PembrolizumabGiuseppe Di Lorenzo, Massimo Di Maio, Carlo Buonerba
Current Opinion in Oncology|February 24, 2005
Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trialsFrancesco Perrone, Massimo Di Maio, Alfredo Budillon, et al.
Current Drug Targets|March 31, 2012
Conventional chemotherapy of advanced pancreatic cancerFrancesco Giuliani, Massimo Di Maio, Giuseppe Colucci, et al.
Pageof 42

Showing results (11-20 of 418) with videos related to

Sort By:
Pageof 42
Pharmaceutical Medicine|May 14, 2025
Association Between Health-Related Quality of Life Measures and Survival Endpoints in Oncology Clinical Trials and in Clinical Decision Making: A Narrative ReviewAnna Amela Valsecchi, Massimo Di Maio
Recenti Progressi in Medicina|August 6, 2019
[Description of adverse events in publications of clinical trials: much room for improvement.]Massimo Di Maio, Andrea Antonuzzo, Paolo Bossi
Cancer Treatment Reviews|October 23, 2012
Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practiceAntonio Rossi, Olga Martelli, Massimo Di Maio
Cancers|September 19, 2020
Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized TrialsFrancesco Facchinetti, Massimo Di Maio, Marcello Tiseo
Expert Review of Respiratory Medicine|February 3, 2017
Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancerAntonio Rossi, Anna La Salvia, Massimo Di Maio
Cancer Management and Research|June 18, 2020
Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The EvidenceEmmanuele De Luca, Donatella Marino, Massimo Di Maio
Translational Lung Cancer Research|March 10, 2016
Raising the bar for enthusiasm when looking at results of randomized phase II trials-the case of sunitinib in small-cell lung cancerMassimo Di Maio, Paolo Bironzo, Giorgio Vittorio Scagliotti
Oncology and Therapy|February 21, 2026
Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus PembrolizumabGiuseppe Di Lorenzo, Massimo Di Maio, Carlo Buonerba
Current Opinion in Oncology|February 24, 2005
Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trialsFrancesco Perrone, Massimo Di Maio, Alfredo Budillon, et al.
Current Drug Targets|March 31, 2012
Conventional chemotherapy of advanced pancreatic cancerFrancesco Giuliani, Massimo Di Maio, Giuseppe Colucci, et al.
Pageof 42